<DOC>
	<DOCNO>NCT00456092</DOCNO>
	<brief_summary>This study look preliminary efficacy safety CC-10004 v placebo patient active psoriatic arthritis . The pharmacokinetics compound patient also explore , biopsy take skin knee synovium look activity drug relevant tissue .</brief_summary>
	<brief_title>Phase II Study With CC-10004 Psoriatic Arthritis</brief_title>
	<detailed_description>This study look preliminary efficacy safety CC-10004 v placebo patient active psoriatic arthritis . Participants must minimum 6 month history psoriatic arthritis qualify . Prior implementation Amendment 1/UK3 study 3 phase - pre-randomisation 35 day , 84 day treatment 28 day follow . After implementation Amendment 1/UK3 , study 4 phase - pre-randomization 35 day , 84 day treatment placebo control treatment phase , 84 day treatment active treatment extension phase 28 day follow . Treatment group 40 milligram ( mg ) daily ( od ) , 20 mg twice daily ( bd ) placebo . To ameliorate dose dependent adverse event CC-10004 ( headache gastro-intestinal ( GI ) disturbance ) dose titration 10mg od ( placebo ) day 1 3 follow 20 mg od ( placebo ) day 4 7 first week dosing . Patients change placebo active treatment entry extension phase undergo dose titration 10mg od day 85 87 follow 20mg od day 88 91 . Assessments take place week 1 every 2 week treatment phase . Plasma pharmacokinetics CC-10004 evaluate subset patient active treatment group placebo control treatment phase . Normal psoriatic skin biopsy and/or synovial biopsy take evaluation histopathology biomarkers subsets patient treatment group .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Apremilast</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Diagnosis psoriatic arthritis ( Moll Wright Criteria ) , include symmetrical asymmetrical peripheral joint involvement least 6 month Active psoriatic arthritis time screen baseline define : 3 swollen joint AND 3 tender joint Negative rheumatoid factor ( RF ) If use methotrexate , methotrexate least 168 day ( 24 week ) stable dose least 56 day prior screen throughout study If use oral corticosteroid , stable dose prednisone ≤ 10 mg/day equivalent least 28 day prior screen throughout study If use nonsteroidal antiinflammatory drug ( NSAID ) therapy , stable dose least 14 day prior screen throughout study Must meet follow laboratory criterion : Hemoglobin ≥ 9 g/dL Hematocrit ≥ 27 % White blood cell ( WBC ) count ≥ 3000 /μL ( ≥ 3.0 X 109/L ) &lt; 20,000/μL ( &lt; 20 X 10^9/L ) Neutrophils ≥ 1500 /μL ( ≥ 1.5 X 10^9/L ) Platelets ≥ 100,000 /μL ( ≥ 100 X 10^9/L ) Serum creatinine ≤ 1.5 mg/dL ( ≤ 132.6 μmol/L ) Total bilirubin ≤ 2.0 mg/dL Aspartate transaminase ( AST [ serum glutamic oxaloacetic transaminase , SGOT ] ) alanine transaminase ( ALT [ serum glutamate pyruvic transaminase , SGPT ] ) ≤ 1.5x upper limit normal ( ULN ) Females childbearing potential ( FCBP ) must negative urine pregnancy test screening ( Visit 1 ) . In addition , sexually active FCBP must agree use TWO adequate form contraception study medication . A FCBP must agree pregnancy test every 28 day study medication Males ( include vasectomy ) must agree use barrier contraception ( latex condom ) engage reproductive sexual activity FCBP study medication least 84 day take last dose study medication History clinically significant cardiac , endocrinologic , pulmonary , neurologic , psychiatric , hepatic , renal , hematologic , immunologic , major disease Any condition , include presence laboratory abnormality , place subject unacceptable risk he/she participate study confounds ability interpret data study Pregnant lactate female History active Mycobacterium tuberculosis infection ( subspecies ) within 3 year prior screen visit . Infections occur &gt; 3 year prior entry must effectively treat . History incompletely treat latent Mycobacterium tuberculosis infection ( indicated positive Purified Protein Derivative [ PPD ] skin test vitro test [ T SPOT®.TB , QuantiFERON Gold® ] ) Clinically significant abnormality chest xray ( CXR ) screen Current erythrodermic , guttate , pustular form psoriasis History infect joint prosthesis within past 5 year Systemic therapy psoriasis and/or psoriatic arthritis ( except methotrexate , ≤ 10 mg/day prednisone equivalent , NSAIDs ) include , limited , sulfasalazine , leflunomide , chloroquine , hydroxychloroquine , gold compound , parenteral corticosteroid ( include intraarticular ) , penicillamine , cyclosporine , oral retinoids , mycophenolate mofetil , thioguanine , hydroxyurea , sirolimus , tacrolimus , azathioprine , fumaric acid ester within 28 day randomization throughout study Topical therapy treatment psoriasis include , limited topical steroid , topical vitamin A D analog preparation , tacrolimus , pimecrolimus , anthralin within 14 day randomization ( Note : Topical background therapy treatment psoriasis allow , except within 24 hour study visit , follow : mild moderate potency corticosteroid treatment palm , face , scalp , axilla , plantar surface , groin accordance manufacturer 's suggested usage . Nonmedicated emollient [ eg , Eucerin® ] tar shampoo also allow . ) Phototherapy ( ultraviolet light A [ UVA ] , narrowband ultraviolet light B [ NBUVB ] , psoralens longwave ultraviolet radiation [ PUVA ] ) within 28 day prior randomization Etanercept use within 56 day prior randomization Adalimumab , efalizumab , infliximab use within 84 day prior randomization Alefacept use within 168 day ( 24 week ) prior randomization Use intraarticular corticosteroid within 28 day prior randomization Use investigational medication within 28 day prior randomization 5 halflives know ( whichever longer ) Any clinically significant abnormality 12lead ECG screen Highrisk factor ( ) , history , human immunodeficiency virus ( HIV ) , hepatitis B , hepatitis C virus infection History malignancy within previous 5 year ( except treat basalcell skin carcinoma ( ) and/or few 3 treat squamouscell skin carcinoma ) Evidence skin condition time screen visit would interfere evaluation effect study medication psoriasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>psoriatic arthritis</keyword>
	<keyword>ACR</keyword>
	<keyword>PASI</keyword>
	<keyword>DAS</keyword>
	<keyword>pharmacokinetic</keyword>
	<keyword>biopsy</keyword>
</DOC>